Xiaoyan Si

机构：Federal Highway Administration, North China University of Science and Technology, Heilongjiang University of Chinese Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital, Zhengzhou University, CCCC Highway Consultants (China), Zhengzhou Central Hospital, Second Affiliated Hospital of Nanjing Medical University, Nanjing Medical University · ORCID：0000-0003-2913-3045

发表论文 119 篇 · 总被引 1320 次 · h-index 18

代表论文

• Single-cell profiling identifies IL1Bhi macrophages associated with inflammation in PD-1 inhibitor-induced inflammatory arthritis (2024 · Nature Communications · 被引 41)
• Management and treatment of severe immune-related hepatotoxicity based on clinical and pathological characteristics (2024 · Hepatology International · 被引 15)
• Safety and Efficacy of the First Subcutaneous ICI , Envafolimab, in the Treatment of Advanced Lung Cancer Patients: A Real‐World Study (2025 · Thoracic Cancer · 被引 5)
• Chinese Expert Consensus on the Diagnosis and Treatment of Inflammatory Myofibroblastic Tumor (2025 · Thoracic Cancer · 被引 5)
• Clinicopathological Characteristics of Inflammatory Myofibroblastic Tumor: A Single Center Retrospective Cohort Study (2024 · Thoracic Cancer · 被引 5)
• Comparative efficacy and safety of anlotinib and topotecan as second-line treatment in small cell lung cancer: a retrospective cohort study (2024 · Translational Lung Cancer Research · 被引 5)